BCL2 and breast cancer: This pathway then inactivates glycogen kinase synthase-3 (GSK-3), Bcl-2-associated agonist of cell death (BAD), and fork-head in rhabdomyosarcoma (FKHR), leading to apoptosis-resistant BC cell (Fig. 5) [89].